The protein is overexpressed in tumors with a more malignant phenotype characteristic and its expression correlates with the risk of BC relapse.6 In mice, pharmacologic activation of α2‐AR enhances mammary tumor growth.7 Consistently, in in vitro studies, cell proliferation and migration capacity are increased when mammary tumor cells are treated with specific α2‐AR agonists, such as clonidine.4, 8 Furthermore, the α2‐AR antagonist rauwolscine reverses the effects of the agonists and inhibits cell proliferation and tumor growth.7, 8, 9. The gene discussed is ADORA2A; the disease is breast cancer.